Resources Repository
-
ReviewPublication 2012Applying Decision Science to Managing National Forests
This publication is an example of the application of decision science to the management of …
This publication is an example of the application of decision science to the management of federal public forests, in particular to meet sustainability goals and multiple use regulations. Through three case studies, the authors describe four stages of a decision analytic approach: problem structuring (framing the problem and defining objectives and evaluation criteria), problem analysis (defining alternatives, evaluating likely consequences, identifying key uncertainties, and analyzing tradeoffs), decision point (identifying the preferred alternative), and implementation and monitoring…
Decision Analysis | Value of Information | Risk Analysis | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment | Government/Law -
ReviewPublication 2011Simulation Models of Obesity: A Review of the Literature
Simulation models combine information from a variety of sources to provide a useful tool for …
Simulation models combine information from a variety of sources to provide a useful tool for examining how the effects of obesity unfold over time and impact population health. They can aid in the understanding of the complex interaction of the drivers of diet and activity and their relation to health outcomes. This paper provided an overview of different types of simulation models used to evaluate the potential impact of policies to address the obesity epidemic.…
Decision Analysis | Mathematical Models | State-Transition | Microsimulation | Calibration/Validation | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Economics/Finance | Food/Agriculture | Health/Medicine -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Decision Analysis | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReviewPublication 2004Decision Analysis Applications in Operations Research
This article reviews trends and developments in decision analysis applications, based primarily on a survey of …
This article reviews trends and developments in decision analysis applications, based primarily on a survey of decision analysis applications published in the period 1990–2001 in major English-language operations research and closely related journals. It serves as a guide to those interested in recent applications in specific areas or in applications that illustrate the use of particular methods. The authors identify and discuss noteworthy trends in, and developments affecting, published applications, including those in computer software and…
Decision Analysis | Operations Research | Business/Industry | Health/Medicine -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ReviewPublication 2021Review of Web-Based Tools for Value-of-Information Analysis
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial …
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial design, and provide information for decisions about reimbursement. The authors review existing web-based tools to facilitate VOI calculations. These include Sheffield Accelerated Value of Information (SAVI), the web interface to the BCEA (Bayesian Cost-Effectiveness Analysis) R package (BCEAweb), Rapid Assessment of Need for Evidence (RANE), and Value of Information for Cardiovascular Trials and Other Comparative Research (VICTOR).
Decision Theory | Priority Setting/Ethics | Value of Information | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America -
ReviewPublication 2018Equity Considerations in CEA: Rotavirus Vaccine in LMIC's
The authors used a systematic review of the literature to identify economic evaluations of rotavirus …
The authors used a systematic review of the literature to identify economic evaluations of rotavirus vaccine in LMICs and assess the extent to which equity was considered in the objectives, analysis, and results. They used equity-related indicators provided in the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria resulting in 18 unique indicators tracked. The authors found that some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented…
Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Health/Medicine | Global -
ReviewPublication 2018Patient Variability Seldom Assessed in Cost-Effectiveness Studies
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether …
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether each cost-effectiveness analysis (CEA) study reported subgroup results and collected data on the defining characteristics of these subgroups. Since estimates can vary across patient subgroups when characteristics are influenced by preferences, outcome risks, treatment effectiveness, life expectancy, or associated costs it can be important to track and report these differences. The authors identified whether any of the CEA subgroup results…
Preferences/Values | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Policy/Regulation | Health/Medicine | Global